TAT(SZ:002433)2015-04-27 16:00Financial Performance - The company's revenue for the first quarter of 2015 was CNY 338,299,842.10, representing a 96.58% increase compared to CNY 172,093,860.73 in the same period last year[8]. - Net profit attributable to shareholders was CNY 34,699,280.67, up 15.06% from CNY 30,158,028.25 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was CNY 34,201,447.00, reflecting a 17.58% increase from CNY 29,086,622.42 in the previous year[8]. - Basic and diluted earnings per share decreased by 54.55% to CNY 0.05 from CNY 0.11 in the previous year[8]. - The net profit attributable to shareholders for the first half of 2015 is expected to range from 74.68 million to 80.65 million RMB, representing a growth of 25% to 35% compared to 59.74 million RMB in the same period of 2014[27]. - The increase in net profit is attributed to the growth in traditional Chinese medicine and e-commerce business[27]. Cash Flow and Operating Activities - The net cash flow from operating activities was negative at CNY -114,261,784.08, a decline of 528.12% compared to CNY -18,191,191.96 in the same period last year[8]. - Net cash flow from operating activities decreased by CNY 96,070,592.12, a decline of 528.12%, due to higher payments for goods, health industry development, and related taxes[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,556,977,741.25, an increase of 1.42% from CNY 4,493,309,540.47 at the end of the previous year[8]. - Net assets attributable to shareholders increased by 1.35% to CNY 3,753,323,490.13 from CNY 3,703,298,671.46 at the end of the previous year[8]. - Total liabilities increased significantly, with accounts payable to employees rising by CNY 1,062,736.65, a growth of 73.47%[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,261[12]. - The largest shareholder, Taian Group Co., Ltd., held 28.01% of the shares, amounting to 203,536,000 shares[12]. Operating Revenue and Costs - Operating revenue increased by CNY 166,205,981.37, a growth of 96.58%, primarily due to the consolidation of Guangdong Kang Aido Chain Pharmacy Co., Ltd. and Shanghai Tai'an Tang Pharmacy Chain Co., Ltd.[18]. - Operating costs rose by CNY 117,668,395.78, an increase of 116.50%, in line with the growth in operating revenue[18]. - Sales expenses surged by CNY 32,013,436.06, a growth of 273.32%, attributed to increased advertising, marketing, and personnel costs[18]. Investments and Income - Investment income increased by CNY 1,934,715.43, a growth of 100.00%, due to returns from bank principal-protected financial products[19]. - Cash received from investment recovery increased by CNY 271,000,000.00, a growth of 100.00%, due to the maturity of financial products[22]. Government Support and Commitments - The company received government subsidies totaling CNY 625,999.98 during the reporting period[9]. - The company commits to distributing no less than 30% of its distributable profits in cash annually for the next three years, barring any significant investment plans or major cash expenditures[25]. - The company has no outstanding commitments that have not been fulfilled, and all commitments are being executed as planned[26]. Securities and Investments - The company does not hold any securities investments during the reporting period[28]. - The company does not hold shares in any other listed companies during the reporting period[29].